Chun-Peng Pai, Han Wang, Darcie D Seachrist, Neel Agarwal, Joshua A Adams, Zhenghao Liu, Ruth A Keri, Kaixiang Cao, William P Schiemann, Hung-Ying Kao
The alternative splicing of PML precursor mRNA gives rise to various PML isoforms, yet their expression profile in breast cancer cells remains uncharted. We discovered that PML1 is the most abundant isoform in all breast cancer subtypes, and its expression is associated with unfavorable prognosis in estrogen receptor-positive (ER+) breast cancers. PML depletion reduces cell proliferation, invasion, and stemness, while heterologous PML1 expression augments these processes and fuels tumor growth and resistance to fulvestrant, an FDA-approved drug for ER+ breast cancer, in a mouse model...
April 16, 2024: Cell Death and Differentiation